NantKwest (NK) Stock Price, News & Analysis

Company Overview

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $2.55 to $2.67
• 50-Day Range: $16.09 to $38.70
• 52-Week Range: $2.52 to $45.42
• Volume: 3.30 million shs
• Average Volume: 1.57 million shs
• Market Capitalization: $285.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NK Stock Analysis - Frequently Asked Questions

How were NantKwest's earnings last quarter?

NantKwest, Inc. (NASDAQ:NK) released its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.02. The biotechnology company had revenue of $0.02 million for the quarter. NantKwest had a negative trailing twelve-month return on equity of 56.06% and a negative net margin of 76,658.58%.

When did NantKwest IPO?

NantKwest (NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.

What other stocks do shareholders of NantKwest own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NantKwest investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Dynavax Technologies (DVAX) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 5/11/2020
• Today: 4/25/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NK
• CIK: 1326110
• Web: www.nantkwest.com
• Phone: 858-633-0300
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-65,790,000.00
• Net Margins: -76,658.58%
• Pretax Margin: N/A
• Return on Equity: -56.06%
• Return on Assets: -46.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.74
• Quick Ratio: 4.74

Sales & Book Value

• Annual Sales: $40,000.00
• Price / Sales: 7,353.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.23 per share
• Price / Book: 2.19

Miscellaneous

• Outstanding Shares: 109,345,000
• Free Float: N/A
• Market Cap: $294.14 million
• Optionable: Not Optionable
• Beta: 2.61